How to buy Biofrontera stock

Biofrontera AG is a biotechnology business based in the US. Biofrontera shares (BFRA) are listed on the NASDAQ and all prices are listed in US Dollars. Biofrontera employs 155 staff and has a market cap (total outstanding shares value) of USD$171 million.

How to buy shares in Biofrontera

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Biofrontera. Find the stock by name or ticker symbol: BFRA. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Biofrontera reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Biofrontera, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Biofrontera. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Biofrontera share price

Use our graph to track the performance of BFRA stocks over time.

Biofrontera shares at a glance

• Key figures

Information last updated 2021-02-23.

52-week range	USD$5.2645 - USD$41.9167
50-day moving average	USD$8.0268
200-day moving average	USD$8.393
Wall St. target price	USD$12
PE ratio	140.9298
Dividend yield	N/A (0.37%)
Earnings per share (TTM)	USD$-0.762

Buy Biofrontera shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Biofrontera stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Biofrontera AG by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Biofrontera financials

Gross profit TTM	USD$26.4 million
Return on assets TTM	-8.44%
Return on equity TTM	-255.71%
Profit margin	-50.96%
Book value	$0.678
Market capitalisation	USD$171 million

TTM: trailing 12 months

Shorting Biofrontera shares

There are currently 2,623 Biofrontera shares held short by investors – that's known as Biofrontera's "short interest". This figure is 89.6% down from 25,119 last month.

There are a few different ways that this level of interest in shorting Biofrontera shares can be evaluated.

Biofrontera's "short interest ratio" (SIR)

Biofrontera's "short interest ratio" (SIR) is the quantity of Biofrontera shares currently shorted divided by the average quantity of Biofrontera shares traded daily (recently around 87433.333333333). Biofrontera's SIR currently stands at 0.03. In other words for every 100,000 Biofrontera shares traded daily on the market, roughly 30 shares are currently held short.

However Biofrontera's short interest can also be evaluated against the total number of Biofrontera shares, or, against the total number of tradable Biofrontera shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biofrontera's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Biofrontera shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Biofrontera shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biofrontera.

Find out more about how you can short Biofrontera stock.

Biofrontera share price volatility

Over the last 12 months, Biofrontera's shares have ranged in value from as little as $5.2645 up to $41.9167. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biofrontera's is 1.4649. This would suggest that Biofrontera's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Biofrontera overview

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

Frequently asked questions

• What percentage of Biofrontera is owned by institutions?

  Currently 0.054% of Biofrontera shares are held by institutions.

• How many people work for Biofrontera?

  Latest data suggests 155 work at Biofrontera.

• When does the fiscal year end for Biofrontera?

  Biofrontera's fiscal year ends in December.

• Where is Biofrontera based?

  Biofrontera's address is: Hemmelrather Weg 201, Leverkusen, Germany, 51377

• What is Biofrontera's ISIN number?

  Biofrontera's international securities identification number is: US09075G1058

• What is Biofrontera's CUSIP number?

  Biofrontera's Committee on Uniform Securities Identification Procedures number is: 09075G105